formation-bio
(2)
David Steinberg
David Steinberg is Chief Business Officer at Formation Bio, an AI-native pharmaceutical company in New York, where he runs in- and out-licensing and pipeline strategy. A serial biotech company builder, he co-founded PureTech Health and served as its Chief Innovation Officer, was a General Partner at Longwood Fund, and founded or led a string of NASDAQ-listed and venture-backed companies including Pyxis Oncology, Vor Biopharma, Vedanta Biosciences and Be Biopharma. He pairs a Cornell biology degree with a University of Chicago Booth MBA and a career that began in R&D and strategy consulting.
Benjamine Liu
Benjamine Liu is the co-founder and CEO of Formation Bio, an AI-native pharmaceutical company in New York that licenses and develops its own drug pipeline. A Rhodes Scholar with a DPhil from Oxford, he started the company (originally TrialSpark) in 2016 after concluding during his graduate work that clinical trials, not discovery, were the real bottleneck slowing new treatments from reaching patients. Formation Bio has raised over $610 million, including a $372 million Series D led by a16z with backing from Sanofi.